US Stock MarketDetailed Quotes

ELVN Enliven Therapeutics

Watchlist
  • 21.000
  • -0.460-2.14%
Close Mar 7 16:00 ET
  • 21.000
  • 0.0000.00%
Post 16:01 ET
1.03BMarket Cap-11.65P/E (TTM)

About Enliven Therapeutics Company

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

Company Profile

SymbolELVN
Company NameEnliven Therapeutics
Listing DateMar 12, 2020
Founded2019
CEOMr. Sam Kintz, M.B.A.
MarketNASDAQ
Employees46
Fiscal Year Ends12-31
Address6200 Lookout Road
CityBoulder
ProvinceColorado
CountryUnited States of America
Zip Code80301
Phone1-720-647-8519
Websitehttp://www.enliventherapeutics.com

Company Executives

  • Name
  • Position
  • Salary
  • Sam Kintz, M.B.A.
  • President, Chief Executive Officer and Director
  • 8.28M
  • Benjamin Hohl
  • Head of Corporate Development, Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Helen Collins, M.D.
  • Chief Medical Officer
  • 4.06M
  • Dr. Anish Patel, Pharm.D.
  • Chief Operating Officer
  • --
  • Dr. Richard Heyman, PhD
  • Chairman of the Board
  • 664.11K
  • Dr. Rahul D. Ballal, PhD
  • Director
  • 1.87M
  • Dr. Lori Anne Kunkel, M.D.
  • Director
  • --
  • Jacob Bauer, M.B.A.
  • Independent Director
  • 551.21K
  • Rishi Gupta, J.D.
  • Independent Director
  • 538.26K
  • Dr. Mika Derynck, M.D.
  • Independent Director
  • 541.48K
  • Dr. Andrew Phillips, PhD
  • Independent Director
  • 542.95K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
NEW WELLLINK
871634
+30.00%
VIBO
871245
+29.99%
MTD
835579
+29.98%
4
REFORMER
833030
+29.98%
5
Hunan Sundy Science And Technology
300515
+20.02%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Trump's comeback to the Office
Following Trump's Policies to Seek Investment Opportunities
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio? Show More
FOMC Press Conference, January 29, 2025